Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CC-92480 in Healthy Subjects
NCT03803644Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mezigdomide in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at Day 1, Time to Maximum Plasma Concentration at Day 1 and 6 more. Started Dec 2018; status: completed.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03803644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803644.